


# Accepted Manuscript



Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study

Melissa P. DelBello, MD, MS, Robert Goldman, PhD, Debra Phillips, BA, Ling Deng, PhD, Josephine Cucchiaro, PhD, Antony Loebel, MD

PII: S0890-8567(17)31772-0

DOI: [10.1016/j.jaac.2017.10.006](https://doi.org/10.1016/j.jaac.2017.10.006)

Reference: JAAC 1983

To appear in: *Journal of the American Academy of Child & Adolescent Psychiatry*

Received Date: 3 July 2017

Revised Date: 2 October 2017

Accepted Date: 5 October 2017

Please cite this article as: DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A, Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study, *Journal of the American Academy of Child & Adolescent Psychiatry* (2017), doi: 10.1016/j.jaac.2017.10.006.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression:  
A Double-Blind, Placebo-Controlled Study**

RH = Lurasidone for BP Depression in Youth

Melissa P. DelBello, MD, MS, Robert Goldman, PhD, Debra Phillips, BA, Ling Deng, PhD,  
Josephine Cucchiaro, PhD, Antony Loebel, MD

This article is discussed in an editorial by Dr. Jon McClellan on page xx.

Accepted October 6, 2017

Dr. DelBello is with the Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH. Dr. Goldman is with Sunovion Pharmaceuticals Inc, Marlborough, MA. Drs. Deng, Cucchiaro, Loebel, and Ms. Phillips are with Sunovion Pharmaceuticals Inc, Fort Lee, NJ.

This work is sponsored by Sunovion Pharmaceuticals Inc.

Dr. Deng served as the statistical expert for this research.

The authors wish to thank Edward Schweizer, MD, of Paladin Consulting Group, who provided editorial and medical writing support under the direction of the authors, that was funded by Sunovion Pharmaceuticals.

Disclosure: Dr. DelBello has received grant or research support from National Institute of Mental Health, the National Institute of Diabetes and Digestive and Kidney Diseases, the Patient-Centered Outcomes Research Institute, Supernus, Sunovion, Otsuka, Pfizer, Lundbeck, and Shire. She has served on the advisory board/DSMB of Sunovion, Neuronetics, Akili, Supernus, Lundbeck, and Johnson and Johnson. She has served as a consultant to Johnson and Johnson, Takeda, and Sunovion. She has served on the editorial board of *Bipolar Disorders* (Section Editor, Pediatrics) and the *Journal of Child and Adolescent Psychopharmacology* (Associate Editor, Neuroimaging). She has received honoraria from American Academy of Child and Adolescent Psychiatry Institute presentations. She has served on the speakers' bureau of Sunovion and Otsuka. She has received travel expenses from Sunovion and Supernus. Drs. Goldman, Deng, Cucchiaro, Loebel, and Ms. Phillips are employees of Sunovion Pharmaceuticals Inc.

Correspondence to Melissa P. DelBello, MD, University of Cincinnati College of Medicine, Department of Psychiatry, 231 Bethesda Ave., P.O. Box 670559, Cincinnati, OH 45267; email: delbelmp@email.uc.edu.

Download English Version:

<https://daneshyari.com/en/article/6795643>

Download Persian Version:

<https://daneshyari.com/article/6795643>

[Daneshyari.com](https://daneshyari.com)